DUBLIN, October 27, 2017 /PRNewswire/ --
The "IDO Inhibitors - A Pipeline Analysis Report" report has been added to Research and Markets' offering.
The report covers the present scenario and the growth prospects of the IDO inhibitors. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The IDO (indoleamine 2,3-dioxygenase 1, IDO1, IDO-1, INDO, indoleamine-pyrrole 2,3-dioxygenase) inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global IDO inhibitors market. Most of the pipeline therapeutics are in early stage of development, the market is yet to witness first IDO inhibitor launch and its impact on overall oncology market.
Indoleamine-2,3-dioxygenase (IDO) is one of the several immune checkpoints involved in tumor immune escape. It is an intracellular heme-containing enzyme that initiates the first and rate-limiting step of tryptophan degradation along with the kynurenine pathway. By inhibiting IDO, researchers hope to restore immune system responses so that cancer cells can be more easily identified and destroyed.
As most of the IDO inhibitors are currently in the very nascent stage, predicting the future is not sensible at this point of time. However, if it succeeds to enter the market in coming years, then IDO inhibitors may not only transform the way to treat advanced melanoma, but also how the treatment for non-small lung cancer, triple-negative breast cancer, and bladder cancer are being carried out with the existing therapies. Most likely that would be huge news for the researchers and the patients as well.
The global IDO inhibitors market is still to witness its first approval for the various type of solid tumors. The majority of the pipeline molecules are still in pre-clinical stage, a few being in Phase II, and only one candidate made its way to Phase III stage of development so far.
- Bristol-Myers Squibb
- Kyowa Hakko Kirin
Key Topics Covered:
Part 01: Executive Summary
Part 02: Scope Of The Report
Part 03: Research Methodology
Part 04: Ido Inhibitors: An Insight
Part 05: Regulatory Framework
Part 06: Pipeline Landscape
Part 07: Comparative Analysis
Part 08: Indication Analysis
Part 09: Therapeutic Assessment By Therapy
Part 10: Therapeutic Assessment By Roa
Part 11: Therapeutic Assessment By Molecule Type
Part 12: Key Companies
Part 13: Appendix
For more information about this report visit https://www.researchandmarkets.com/research/3vcfsb/ido_inhibitors
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets